The first experience with sodium‐glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure
Abstract In congenitally corrected transposition of the great arteries, the morphological right ventricle supports the systemic circulation. This chronic exposure to pressure overload ultimately leads to systemic right ventricular (sRV) dysfunction and heart failure. Pharmacological options for the...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.13871 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832540303195635712 |
|---|---|
| author | Anastasia D. Egorova Marieke Nederend Laurens F. Tops Hubert W. Vliegen Monique R.M. Jongbloed Philippine Kiès |
| author_facet | Anastasia D. Egorova Marieke Nederend Laurens F. Tops Hubert W. Vliegen Monique R.M. Jongbloed Philippine Kiès |
| author_sort | Anastasia D. Egorova |
| collection | DOAJ |
| description | Abstract In congenitally corrected transposition of the great arteries, the morphological right ventricle supports the systemic circulation. This chronic exposure to pressure overload ultimately leads to systemic right ventricular (sRV) dysfunction and heart failure. Pharmacological options for the treatment of sRV failure are poorly defined and no solid recommendations are made in the most recent guidelines. Sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors are a new class of antihyperglycaemic drugs that have been demonstrated to significantly reduce the risk of worsening heart failure and death from cardiovascular causes in patients with chronic heart failure with reduced left ventricular ejection fraction, yet no data are available in sRV patients. We report on the treatment and clinical follow‐up of a patient with advanced heart failure and poor sRV function in the context of congenitally corrected transposition of the great arteries, who did not tolerate sacubitril/valsartan and had a high burden of heart‐failure‐related hospitalizations. Treatment with dapagliflozin was well tolerated and resulted in (small) subjective and objective functional and echocardiographic improvement and a reduction in heart‐failure‐related hospitalizations. |
| format | Article |
| id | doaj-art-202fa3d15fca4d448edea07800a84e43 |
| institution | Kabale University |
| issn | 2055-5822 |
| language | English |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj-art-202fa3d15fca4d448edea07800a84e432025-02-05T05:22:10ZengWileyESC Heart Failure2055-58222022-06-01932007201210.1002/ehf2.13871The first experience with sodium‐glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failureAnastasia D. Egorova0Marieke Nederend1Laurens F. Tops2Hubert W. Vliegen3Monique R.M. Jongbloed4Philippine Kiès5CAHAL, Center for Congenital Heart Disease Amsterdam Leiden Leiden University Medical Center Leiden The NetherlandsCAHAL, Center for Congenital Heart Disease Amsterdam Leiden Leiden University Medical Center Leiden The NetherlandsDepartment of Cardiology, Leiden Heart‐Lung Center Leiden University Medical Center Albinusdreef 2 Leiden 2333 ZA The NetherlandsCAHAL, Center for Congenital Heart Disease Amsterdam Leiden Leiden University Medical Center Leiden The NetherlandsCAHAL, Center for Congenital Heart Disease Amsterdam Leiden Leiden University Medical Center Leiden The NetherlandsCAHAL, Center for Congenital Heart Disease Amsterdam Leiden Leiden University Medical Center Leiden The NetherlandsAbstract In congenitally corrected transposition of the great arteries, the morphological right ventricle supports the systemic circulation. This chronic exposure to pressure overload ultimately leads to systemic right ventricular (sRV) dysfunction and heart failure. Pharmacological options for the treatment of sRV failure are poorly defined and no solid recommendations are made in the most recent guidelines. Sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors are a new class of antihyperglycaemic drugs that have been demonstrated to significantly reduce the risk of worsening heart failure and death from cardiovascular causes in patients with chronic heart failure with reduced left ventricular ejection fraction, yet no data are available in sRV patients. We report on the treatment and clinical follow‐up of a patient with advanced heart failure and poor sRV function in the context of congenitally corrected transposition of the great arteries, who did not tolerate sacubitril/valsartan and had a high burden of heart‐failure‐related hospitalizations. Treatment with dapagliflozin was well tolerated and resulted in (small) subjective and objective functional and echocardiographic improvement and a reduction in heart‐failure‐related hospitalizations.https://doi.org/10.1002/ehf2.13871Systemic right ventricleHeart failureCongenital heart diseaseAdult congenital heart diseaseChronic heart failureSodium‐glucose cotransporter inhibitor |
| spellingShingle | Anastasia D. Egorova Marieke Nederend Laurens F. Tops Hubert W. Vliegen Monique R.M. Jongbloed Philippine Kiès The first experience with sodium‐glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure ESC Heart Failure Systemic right ventricle Heart failure Congenital heart disease Adult congenital heart diseaseChronic heart failureSodium‐glucose cotransporter inhibitor |
| title | The first experience with sodium‐glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure |
| title_full | The first experience with sodium‐glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure |
| title_fullStr | The first experience with sodium‐glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure |
| title_full_unstemmed | The first experience with sodium‐glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure |
| title_short | The first experience with sodium‐glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure |
| title_sort | first experience with sodium glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure |
| topic | Systemic right ventricle Heart failure Congenital heart disease Adult congenital heart diseaseChronic heart failureSodium‐glucose cotransporter inhibitor |
| url | https://doi.org/10.1002/ehf2.13871 |
| work_keys_str_mv | AT anastasiadegorova thefirstexperiencewithsodiumglucosecotransporter2inhibitorforthetreatmentofsystemicrightventricularfailure AT mariekenederend thefirstexperiencewithsodiumglucosecotransporter2inhibitorforthetreatmentofsystemicrightventricularfailure AT laurensftops thefirstexperiencewithsodiumglucosecotransporter2inhibitorforthetreatmentofsystemicrightventricularfailure AT hubertwvliegen thefirstexperiencewithsodiumglucosecotransporter2inhibitorforthetreatmentofsystemicrightventricularfailure AT moniquermjongbloed thefirstexperiencewithsodiumglucosecotransporter2inhibitorforthetreatmentofsystemicrightventricularfailure AT philippinekies thefirstexperiencewithsodiumglucosecotransporter2inhibitorforthetreatmentofsystemicrightventricularfailure AT anastasiadegorova firstexperiencewithsodiumglucosecotransporter2inhibitorforthetreatmentofsystemicrightventricularfailure AT mariekenederend firstexperiencewithsodiumglucosecotransporter2inhibitorforthetreatmentofsystemicrightventricularfailure AT laurensftops firstexperiencewithsodiumglucosecotransporter2inhibitorforthetreatmentofsystemicrightventricularfailure AT hubertwvliegen firstexperiencewithsodiumglucosecotransporter2inhibitorforthetreatmentofsystemicrightventricularfailure AT moniquermjongbloed firstexperiencewithsodiumglucosecotransporter2inhibitorforthetreatmentofsystemicrightventricularfailure AT philippinekies firstexperiencewithsodiumglucosecotransporter2inhibitorforthetreatmentofsystemicrightventricularfailure |